Načítá se...
The PI3Kδ inhibitor idelalisib suppresses liver and lung cellular respiration
Idelalisib (an inhibitor of phosphatidylinositol-3-kinase-delta) is approved for treatment of B-cell malignancies, with a Boxed Warning concerning potentially fatal hepatic, lung, and intestinal toxicities. The mechanisms of these tissue-specific adverse events have yet to be elucidated. This in vit...
Uloženo v:
| Vydáno v: | Int J Physiol Pathophysiol Pharmacol |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
e-Century Publishing Corporation
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4697667/ https://ncbi.nlm.nih.gov/pubmed/26823960 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|